Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
bazedoxifene BZA-20 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| bazedoxifene BZA-20 | DRUG | - |
Inclusion Criteria: 1. Generally healthy Asian women 45 years of age or older who are at least 1 year postmenopausal 2. Subjects must qualify for one of the following categories (a or b): 1. Greater than 1 year but less than 5 years postmenopausal with at least one of the ospeoporosis risk fact...
Bazedoxifene BZA-20 is being studied in postmenopausal women, including those with osteoporosis. It is a small molecule in Phase 3 development for postmenopause-related conditions. The completed Phase 3 trial enrolled 500 postmenopausal women in China, South Korea, and Taiwan.
Bazedoxifene BZA-20 targets estrogen receptors ESR2 and ESR1. It is classified as a modulator, meaning it interacts with these receptors rather than simply activating or blocking them. This receptor activity underlies its investigation in postmenopausal endocrine conditions.
Bazedoxifene BZA-20 is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company responsible for the clinical development of this small molecule in the postmenopause endocrine space.
Bazedoxifene BZA-20 is in Phase 3 clinical development. It is investigational and has not been approved. One Phase 3 trial has been completed, and no trials are currently active.
Bazedoxifene BZA-20 has been studied in one completed Phase 3 trial, NCT00384072, titled Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women. It enrolled 500 participants across China, South Korea, and Taiwan and was randomized and double blind.